Characterization of biosimilar biologics: The link between structure and functions

Biosimilar Drug Product Development

Volumn , Issue , 2017, Pages 109-150

  Jefferis, Roy ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85020162296     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781315119878     Document Type: Chapter

References (240)

1. Adams EW, Ratner DM, Seeberger PH, Hacohen N. (2008) Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells. Chembiochem 9(2), 294-303.
2. Ahmed AA, Giddens J, Pincetic A, et al. (2014) Structural characterization of anti-inflammatory immunoglobulin G Fc proteins. Journal of Molecular Biology 426(18), 3166-3179.
3. Alavi A, Arden N, Spector TD, Axford JS. (2000) Immunoglobulin G glycosylation and clinical outcome in rheumatoid arthritis during pregnancy. Journal of Rheumatology 27(6), 1379-1385.
4. Allhorn M, Briceno JG, Baudino L, et al. (2010) T he IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis. Blood 115(24), 5080-5088.
5. Anthony RM, Wermeling F, Ravetch JV. (2012) Novel roles for the IgG Fc glycan. Annals of New York Academy of Sciences 1253, 170-180.
6. Anumula KR. (2012) Quantitative glycan profiling of normal human plasma derived immunoglobulin and its fragments Fab and Fc. Journal of Immunology Methods 382(1-2), 167-176.
7. Aricescu AR, Owens RJ. (2013) Expression of recombinant glycoproteins in mammalian cells: towards an integrative approach to structural biology. Current Opinion in Structural Biology 23(3), 345-356.
8. Arnold JN, Dwek RA, Rudd PM, Sim RB. (2006) Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunology Letters 106(2), 103-110.
9. Ballow M. (2014) Mechanisms of immune regulation by IVIG. Current Opinion in Allergy and Clinical Immunology 14(6), 509-515.
10. Banda NK, Wood AK, Takahashi K, et al. (2008) Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. Arthritis & Rheumatology 58(10), 3081-3089.
11. Barb AW, Meng L, Gao Z, et al. (2012) NMR characterization of immunoglobulin G Fc glycan motion on enzymatic sialylation. Biochemistry 51(22), 4618-4626.
12. Barb AW, Prestegard JH. (2011) NMR analysis demonstrates immunoglobulin G N-glycans are accessible and dynamic. Nature Chemistry and Biology 7(3), 147-153.
13. Beck A, Reichert JM. (2013) Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 5(5), 621-623.
14. Berg EA, Platts-Mills TA, Commins SP. (2014) Drug allergens and food-the cetuximab and galactose-α-1,3-galactose story. Annals of Allergy, Asthma and Immunology 112(2), 97-101.
15. Bertolotti-Ciarlet A, Wang W, Lownes R, et al. (2009) Impact of methionine oxidation on the binding of human IgG1 to Fc Rn and Fc receptors. Molecular Immunology 46(8-9), 1878-1882.
16. Bondt A, Selman MH, Deelder AM, et al. (2013) Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. Journal of Proteome Research 12(10), 4522-4531.
17. Borrok MJ, Jung ST, Kang TH, et al. (2012) Revisiting the role of glycosylation in the structure of human IgG Fc. ACS Chemistry and Biology 7(9), 1596-1602.
18. Bosques CJ, Collins BE, Meador JW, 3rd, et al. (2010) Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteins. Nature Biotechnology 28(11), 1153-1156.
19. Boyd PN, Lines AC, Patel AK. (1995) The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Molecular Immunology 32(17-18), 1311-1318.
20. Burnouf T. (2011) Recombinant plasma proteins. Vox Sang 100(1), 68-83.
21. Burska AN, Hunt L, Boissinot M, et al. (2014) Autoantibodies to posttranslational modifications in rheumatoid arthritis. Mediators of In¥ammation 2014, 492873.
22. Campbell IK, Miescher S, Branch DR, et al. (2014) Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. Journal of Immunology 192(11), 5031-5038.
23. Carter P, Presta L, Gorman CM, et al. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proceedings of National Academy of Science USA 89(10), 4285-4289.
24. Cartron G, Dacheux L, Salles G, et al. (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene. Blood 99(3), 754-758.
25. CFG. (2012) Symbol and text nomenclature for representation of glycan structure. June 15, 2015. Available from: http://glycomics.scripps.edu/CFGnomenclature.pdf.
26. Chelius D, Rehder DS, Bondarenko PV. (2005) Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Analytical Chemistry 77(18), 6004-6011.
27. Chicooree N, Unwin RD, Griffiths JR. (2015) The application of targeted mass spectrometrybased strategies to the detection and localization of post-translational modifications. Mass Spectrometry Reviews 34(6), 595-626.
28. Choe H, Li W, Wright PL, et al. (2003) Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114(2), 161-170.
29. Chumsae C, Gaza-Bulseco G, Sun J, Liu H. (2007) Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody. Journal of Chromatography B Analytical Technology Biomedical Life Sciences 850(1-2), 285-294.
30. Chung CH, Mirakhur B, Chan E, et al. (2008) Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. New England Journal of Medicine 358(11), 1109-1117.
31. Coloma MJ, Trinh RK, Martinez AR, Morrison SL. (1999) Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1→6) dextran antibody. Journal of Immunology 162(4), 2162-2170.
32. Corper AL, Sohi MK, Bonagura VR, et al. (1997) Structure of human IgM rheumatoid factor Fab bound to its autoantigen IgG Fc reveals a novel topology of antibody-antigen interaction. Nature Structural Biology 4(5), 374-381.
33. Correia IR. (2010) Stability of IgG isotypes in serum. MAbs 2(3), 221-232.
34. Costagliola S, Panneels V, Bonomi M, et al. (2002) Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors. EMBO Journal 21(4), 504-513.
35. Crispin M. (2013) Therapeutic potential of deglycosylated antibodies. Proceedings of National Academy of Science USA 110(25), 10059-10060.
36. Daguet A, Watier H. (2011) 2nd Charles Richet et Jules Hericourt workshop: therapeutic antibodies and anaphylaxis; May 31-June 1, 2011, Tours, France. MAbs 3(5), 417-421.
37. Davies AM, Rispens T, den Bleker TH, et al. (2013) Crystal structure of the human IgG4 C(H)3 dimer reveals the role of Arg409 in the mechanism of Fab-arm exchange. Molecular Immunology 54(1), 1-7.
38. Davies J, Jiang L, Pan LZ, et al. (2001) Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FCRIII. Biotechnology and Bioengineering 74(4), 288-294.
39. Deisenhofer J. (1981) Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9-and 2.8-A resolution. Biochemistry 20(9), 2361-2370.
40. Delord JP, Tabernero J, Garcia-Carbonero R, et al. (2014) Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. European Journal of Cancer 50(3), 496-505.
41. Derer S, Kellner C, Rosner T, et al. (2014) Fc engineering of antibodies and antibody derivatives by primary sequence alteration and their functional characterization. Methods in Molecular Biology 1131, 525-540.
42. Diepold K, Bomans K, Wiedmann M, et al. (2012) Simultaneous assessment of Asp isomerization and Asn deamidation in recombinant antibodies by LC-MS following incubation at elevated temperatures. PLoS One 7(1), e30295.
43. Dillon TM, Ricci MS, Vezina C, et al. (2008) Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. Journal of Biological Chemistry 283(23), 16206-16215.
44. Dong X, Storkus WJ, Salter RD. (1999) Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. Journal of Immunology 163(10), 5427-5434.
45. Doores KJ, Bonomelli C, Harvey DJ, et al. (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proceedings of National Academy of Science USA 107(31), 13800-13805.
46. EBE. (2013) Concept paper-considerations in setting specifications. A pril 1 2, 2 016. Available from: http://www.ebe-biopharma.eu/uploads/Modules/Documents/ebeconcept-paper-%E2%80%93-considerations-in-setting-specifications.pdf.
47. Edelman GM, Cunningham BA, Gall WE, et al. (2004) The covalent structure of an entire G.immunoglobulin molecule. Journal of Immunology 173(9), 5335-5342.
48. Einarsdottir HK, Selman MH, Kapur R, et al. (2013) Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G. Glycoconjugation Journal 30(2), 147-157.
49. Elliott S, Egrie J, Browne J, et al. (2004) Control of rHuEPO biological activity: the role of carbohydrate. Experimental Hematology 32(12), 1146-1155.
50. EMA. (2008) Guideline on development, production, characterisation and specifications for monoclonal antibodies and related products. April 1, 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003074.pdf.
51. Ercan A, Cui J, Chatterton DE, et al. (2010) Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis and Rheumatism 62(8), 2239-2248.
52. Estes S, Melville M. (2014) Mammalian cell line developments in speed and efficiency. Advances in Biochemical Engineering and Biotechnology 139, 11-33.
53. Farooq M, Takahashi N, Arrol H, et al. (1997) Glycosylation of polyclonal and paraprotein IgG in multiple myeloma. Glycoconjugation Journal 14(4), 489-492.
54. Farriol-Mathis N, Garavelli JS, Boeckmann B, et al. (2004) Annotation of post-translational modifications in the Swiss-Prot knowledge base. Proteomics 4(6), 1537-1550.
55. FDA. (2014) Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product. May 2 0, 2 014. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf.
56. FDA. (2015a) News release: FDA approves first biosimilar product Zarxio. April 12, 2016. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm.
57. FDA. (2015b) Gazyva (obinutuzumab). April 12, 2016. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm373263.htm.
58. Ferrara C, Brunker P, Suter T, et al. (2006) Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous β1, 4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II. Biotechnology and Bioengineering 93(5), 851-861.
59. Ferrara C, Grau S, Jager C, et al. (2011) Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcRIII and antibodies lacking core fucose. Proceedings of National Academy of Science USA 108(31), 12669-12674.
60. Flynn GC, Chen X, Liu YD, et al. (2010) Naturally occurring glycan forms of human immunoglobulins G1 and G2. Molecular Immunology 47(11-12), 2074-2082.
61. Fortunato ME, Colina CM. (2014) Effects of galactosylation in immunoglobulin G from all-atom molecular dynamics simulations. Journal of Physical Chemistry B 118(33), 9844-9851.
62. Frank M, Walker RC, Lanzilotta WN, et al. (2014) Immunoglobulin G1 Fc domain motions:implications for Fc engineering. Journal of Molecular Biology 426(8), 1799-1811.
63. Franze R, Hirashima C, Link T, et al. (2012) Method for the production of a glycosylated immunoglobulin. EP2493922 A1.
64. Galili U. (2013) Discovery of the natural anti-Gal antibody and its past and future relevance to medicine. Xenotransplantation 20(3), 138-147.
65. Gaza-Bulseco G, Faldu S, Hurkmans K, et al. (2008) Effect of methionine oxidation of a recombinant monoclonal antibody on the binding affinity to protein A and protein G. Journal of Chromatography B Analytical Technology Biomedical Life Science 870(1), 55-62.
66. Ghaderi D, Zhang M, Hurtado-Ziola N, Varki A. (2012) Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation. Biotechnology and Genetic Engineering Reviews 28, 147-175.
67. Ghazavi MK, Johnston GA. (2011) Insulin allergy. Clinical Dermatology 29(3), 300-305.
68. Gillis C, Gouel-Cheron A, Jonsson F, Bruhns P. (2014) Contribution of human FcRs to disease with evidence from human polymorphisms and transgenic animal studies. Frontiers of Immunology 5, 254.
69. Girardi E, Holdom MD, Davies AM, et al. (2009) The crystal structure of rabbit IgG-Fc. Biochemical Journal 417(1), 77-83.
70. Gloster TM, Vocadlo DJ. (2012) Developing inhibitors of glycan processing enzymes as tools for enabling glycobiology. Nature Chemistry and Biology 8(8), 683-694.
71. Goetze AM, Liu YD, Arroll T, et al. (2012) Rates and impact of human antibody glycation in vivo. Glycobiology 22(2), 221-234.
72. Goetze AM, Liu YD, Zhang Z, et al. (2011b) High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 21(7), 949-959.
73. Goetze AM, Zhang Z, Liu L, et al. (2011a) Rapid LC-MS screening for IgG Fc modifications and allelic variants in blood. Molecular Immunology 49(1-2), 338-352.
74. Grinnell BW, Walls JD, Gerlitz B. (1991) Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. Journal of Biological Chemistry 266(15), 9778-9785.
75. Grinnell BW, Yan SB, Macias WL. (2006) Activated protein C. In: Directory of Therapeutic Enzymes. McGrath BM and Walsh G, eds., 69-95. CRC Press, Boca Raton, FL.
76. Guhr T, Bloem J, Derksen NI, et al. (2011) Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 6(6), e21246.
77. Haberger M, Bomans K, Diepold K, et al. (2014) Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: susceptibility vs. functionality of critical quality attributes. MAbs 6(2), 327-339.
78. Hansson K, Stenflo J. (2005) Post-translational modifications in proteins involved in blood coagulation. Journal of Thrombosis and Haemostasis 3(12), 2633-2648.
79. Harris RJ, Kabakoff B, Macchi FD, et al. (2001) Identification of multiple sources of charge heterogeneity in a recombinant antibody. Journal of Chromatography B Biomedical Science Applications 752(2), 233-245.
80. Haryadi R, Zhang PQ, Chan KF, Song ZW. (2013) CHO-gmt5, a novel CHO glycosylation mutant for producing afucosylated and asialylated recombinant antibodies. Bioengineered 4(2), 90-94.
81. Hayes JM, Cosgrave EF, Struwe WB, et al. (2014) Glycosylation and Fc receptors. Current Topics in Microbiology and Immunology 382, 165-199.
82. Holland M, Yagi H, Takahashi N, et al. (2006) Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis. Biochimica Biophysica Acta 1760(4), 669-677.
83. Hospira. (2013) Press release: Hospira’s Inflectra (infliximab) the first biosimilar monoclonal antibody to be approved in Europe. April 12, 2016. Available from: http://phx. corporate-ir. net/phoenix.zhtml?c=175550&p=irol-newsArticle&ID=1853480&highlight.
84. Hossler P. (2012) Protein glycosylation control in mammalian cell culture: past precedents and contemporary prospects. Advances in Biochemical Engineering and Biotechnology 127, 187-219.
85. Houde D, Engen JR. (2013) Conformational analysis of recombinant monoclonal antibodies with hydrogen/deuterium exchange mass spectrometry. Methods in Molecular Biology 988, 269-289.
86. Hristodorov D, Fischer R, Linden L. (2013) With or without sugar? (A)glycosylation of therapeutic antibodies. Molecular Biotechnology 54(3), 1056-1068.
87. Huang L, Biolsi S, Bales KR, Kuchibhotla U. (2006) Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. Analytical Biochemistry 349(2), 197-207.
88. Huang L, Lu J, Wroblewski VJ, et al. (2005) In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Analytical Chemistry 77(5), 1432-1439.
89. Hutterer KM, Hong RW, Lull J, et al. (2013) Monoclonal antibody disulfide reduction during manufacturing: untangling process effects from product effects. MAbs 5(4), 608-613.
90. Jacquemin M. (2010) Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody. Haemophilia 16(102), 16-19.
91. Jefferis R. (2009a) Glycoforms of human IgG in health and disease. Trends in Glycoscience and Glycotechnology 21(2009), 105-117.
92. Jefferis R. (2009b) Aglycosylated antibodies and the methods of making and using them:WO2008030564. Expert Opinion Therapy and Pathology 19(1), 101-105.
93. Jefferis R. (2009c) Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. Trends in Pharmacological Science 30(7), 356-362.
94. Jefferis R. (2011) Aggregation, immune complexes and immunogenicity. MAbs 3(6), 503-504.
95. Jefferis R. (2012) Isotype and glycoform selection for antibody therapeutics. Archives of Biochemistry and Biophysics 526(2), 159-166.
96. Jefferis R. (2014) Monoclonal antibodies: mechanisms of action. In: State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1. Monoclonal Antibody Therapeutics: Structure, Function, and Regulatory Space. Schiel JE, Davis DL, Borisov OV, eds., 35-68. American Chemical Society, Washington, DC.
97. Jefferis R, Lefranc MP. (2009) Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs 1(4), 332-338.
98. Jefferis R, Lund J, Mizutani H, et al. (1990) A comparative study of the N-linked oligosaccharide structures of human IgG subclass proteins. Biochemical Journal 268(3), 529-537.
99. Jefferis R, Lund J, Pound JD. (1998) IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunological Reviews 163, 59-76.
100. Ju MS, Jung ST. (2014) Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics. Current Opinion in Biotechnology 30, 128-139.
101. Kao YH, Laird MW, Schmidt MT, et al. (2013) Prevention of disulfide bond reduction during recombinant production of polypeptides. US8574869 B2.
102. Kaufman RJ, Powell JS. (2013) Molecular approaches for improved clotting factors for hemophilia. Blood 122(22), 3568-3574.
103. Khawli LA, Goswami S, Hutchinson R, et al. (2010) Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs 2(6), 613-624.
104. Khoury GA, Baliban RC, Floudas CA. (2011) Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database. Science Reports 1, Article number 90.
105. Kibe T, Fujimoto S, Ishida C, et al. (1996) Glycosylation and placental transport of immunoglobulin G. Journal of Clinical Biochemistry and Nutrition 21(1), 57-63.
106. Kobata A. (2008) The N-linked sugar chains of human immunoglobulin G: their unique pattern, and their functional roles. Biochimica Biophysica Acta 1780(3), 472-478.
107. Koterba KL, Borgschulte T, Laird MW. (2012) Thioredoxin 1 is responsible for antibody disulfide reduction in CHO cell culture. Journal of Biotechnology 157(1), 261-267.
108. Kozlowski S, Swann P. (2006) Current and future issues in the manufacturing and development of monoclonal antibodies. Advanced Drug Delivery Reviews 58(5-6), 707-722.
109. Krapp S, Mimura Y, Jefferis R, et al. (2003) Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. Journal of Molecular Biology 325(5), 979-989.
110. Kumar A, Bachhawat AK. (2012) Pyroglutamic acid: throwing light on a lightly studied metabolite. Current Science 102, 288-297.
111. Lai T, Yang Y, Ng SK. (2013) Advances in Mammalian cell line development technologies for recombinant protein production. Pharmaceuticals (Basel) 6(5), 579-603.
112. Lammerts van Bueren JJ, Rispens T, Verploegen S, et al. (2011) Anti-galactose-α-1,3-galactose IgE from allergic patients does not bind α-galactosylated glycans on intact therapeutic antibody Fc domains. Nature Biotechnology 29(7), 574-576.
113. Lanucara F, Eyers CE. (2013) Top-down mass spectrometry for the analysis of combinatorial post-translational modifications. Mass Spectrometry Reviews 32(1), 27-42.
114. Leblanc Y, Romanin M, Bihoreau N, Chevreux G. (2014) LC-MS analysis of polyclonal IgGs using IdeS enzymatic proteolysis for oxidation monitoring. Journal of Chromatography B Analytical Technology Biomedical Life Sciences 961, 1-4.
115. Leontyev D, Katsman Y, Ma XZ, et al. (2012) Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 52(8), 1799-1805.
116. Li J, Menzel C, Meier D, Zhang C, Dubel S, Jostock T. (2007) A comparative study of different vector designs for the mammalian expression of recombinant IgG antibodies. Journal of Immunological Methods 318(1-2), 113-124.
117. Li J, Wong CL, Vijayasankaran N, et al. (2012) Feeding lactate for CHO cell culture processes:impact on culture metabolism and performance. Biotechnology and Bioengineering 109(5), 1173-1186.
118. Lim A, Reed-Bogan A, Harmon BJ. (2008) Glycosylation profiling of a therapeutic recombinant monoclonal antibody with two N-linked glycosylation sites using liquid chromatography coupled to a hybrid quadrupole time-of-flight mass spectrometer. Analytical Biochemistry 375(2), 163-172.
119. Liu H, May K. (2012) Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs 4(1), 17-23.
120. Liu J, Jonebring A, Hagstrom J, Nystrom AC, Lovgren A. (2014) Improved expression of recombinant human factor IX by co-expression of GGCX, VKOR and furin. Protein Journal 33(2), 174-183.
121. Liu YD, Goetze AM, Bass RB, Flynn GC. (2011) N-terminal glutamate to pyroglutamate conversion in vivo for human IgG2 antibodies. Journal of Biological Chemistry 286(13), 11211-11217.
122. Liu YD, van Enk JZ, Flynn GC. (2009) Human antibody Fc deamidation in vivo. Biologicals 37(5), 313-322.
123. Louis E, El Ghoul Z, Vermeire S, et al. (2004) Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Alimentary Pharmacology Therapy 19(5), 511-519.
124. Ludeman JP, Stone MJ. (2014) The structural role of receptor tyrosine sulfation in chemokine recognition. British Journal of Pharmacology 171(5), 1167-1179.
125. Lund J, Takahashi N, Pound JD, et al. (1996) Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. Journal of Immunology 157(11), 4963-4969.
126. Lux A, Yu X, Scanlan CN, Nimmerjahn F. (2013) Impact of immune complex size and glycosylation on IgG binding to human FcRs. Journal of Immunology 190(8), 4315-4323.
127. Macdougall IC, Roger SD, de Francisco A, et al. (2012) Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents:new insights. Kidney International 81(8), 727-732.
128. Maeda E, Kita S, Kinoshita M, et al. (2012) Analysis of nonhuman N-glycans as the minor constituents in recombinant monoclonal antibody pharmaceuticals. Analytical Chemistry 84(5), 2373-2379.
129. Malhotra R, Wormald MR, Rudd PM, et al. (1995) Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nature Medicine 1(3), 237-243.
130. Manning G, Whyte DB, Martinez R, et al. (2002) The protein kinase complement of the human genome. Science 298(5600), 1912-1934.
131. Marth JD, Grewal PK. (2008) Mammalian glycosylation in immunity. Nature Reviews in Immunology 8(11), 874-887.
132. Masuda K, Kubota T, Kaneko E, et al. (2007) Enhanced binding affinity for FcRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Molecular Immunology 44(12), 3122-3131.
133. Matsumiya S, Yamaguchi Y, Saito J, et al. (2007) Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. Journal of Molecular Biology 368(3), 767-779.
134. McGrath B. (2006) Factor IX (Protease Zymogen). In: Directory of Therapeutic Enzymes. McGrath BM and Walsh G, eds., 209-238. CRC Press, Boca Raton, FL.
135. Medzihradszky KF, Darula Z, Perlson E, et al. (2004) O-sulfonation of serine and threonine:mass spectrometric detection and characterization of a new posttranslational modification in diverse proteins throughout the eukaryotes. Molecular Cell Proteomics 3(5), 429-440.
136. Merlini G, Comenzo RL, Seldin DC, et al. (2014) Immunoglobulin light chain amyloidosis. Expert Reviews in Hematology 7(1), 143-156.
137. Miescher S, Spycher MO, Amstutz H, et al. (2004) A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcRIIA and FcIIIA genes. Blood 103(11), 4028-4035.
138. Millward TA, Heitzmann M, Bill K, et al. (2008) Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals 36(1), 41-47.
139. Mimura Y, Ashton PR, Takahashi N, et al. (2007) Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry. Journal of Immunological Methods 326(1-2), 116-126.
140. Mimura Y, Church S, Ghirlando R, et al. (2000) The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. Molecular Immunology 37(12-13), 697-706.
141. Mimura Y, Sondermann P, Ghirlando R, et al. (2001) Role of oligosaccharide residues of IgG1-Fc in FcRIIb binding. Journal of Biological Chemistry 276(49), 45539-45547.
142. Mizushima T, Yagi H, Takemoto E, et al. (2011) Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans. Genes to Cells 16(11), 1071-1080.
143. Mossner E, Brunker P, Moser S, et al. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22), 4393-4402.
144. Mullins RJ, James H, Platts-Mills TA, Commins S. (2012) Relationship between red meat allergy and sensitization to gelatin and galactose-α-1,3-galactose. Journal of Allergy and Clinical Immunology 129(5), 1334-1342.
145. Nakagawa T, Natsume A, Satoh M, Niwa R. (2010) Nonfucosylated anti-CD20 antibody potentially induces apoptosis in lymphoma cells through enhanced interaction with FcRIIIb on neutrophils. Leukemia Research 34(5), 666-671.
146. Nakajima C, Kuyama H, Nakazawa T, et al. (2011) A method for N-terminal de novo sequencing of Nα-blocked proteins by mass spectrometry. Analyst 136(1), 113-119.
147. Natsume A, In M, Takamura H, et al. (2008) Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Research 68(10), 3863-3872.
148. NCI. (2016) What is cancer proteomics? April 12, 2016. Available from: http://proteomics. cancer.gov/whatisproteomics.
149. Nesspor TC, Raju TS, Chin CN, et al. (2012) Avidity confers FcR binding and immune effector function to aglycosylated immunoglobulin G1. Journal of Molecular Recognition 25(3), 147-154.
150. NIBRT. (2012) Glycobase. June 15, 2015. Available from: http://glycobase.nibrt.ie/glycobase/about.action.
151. Niwa R, Natsume A, Uehara A, et al. (2005) IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. Journal of Immunological Methods 306(1-2), 151-160.
152. Oaks M, Taylor S, Shaffer J. (2013) Autoantibodies targeting tumor-associated antigens in metastatic cancer: sialylated IgGs as candidate anti-inflammatory antibodies. Oncoimmunology 2(6), e24841.
153. Ogorek C, Jordan I, Sandig V, von Horsten HH. (2012) Fucose-targeted glycoengineering of pharmaceutical cell lines. Methods of Molecular Biology 907, 507-517.
154. Othy S, Topcu S, Saha C, et al. (2014) Sialylation may be dispensable for reciprocal modulation of helper T cells by intravenous immunoglobulin. European Journal of Immunology 44(7), 2059-2063.
155. Ozbabacan SEA, Engin HB, Gursoy A, Keskin O. (2011) Transient protein-protein interactions. Protein Engineering Design & Selection 24(9), 635-648.
156. Pacis E, Yu M, Autsen J, et al. (2011) Effects of cell culture conditions on antibody N-linked glycosylation-what affects high mannose 5 glycoform. Biotechnology and Bioengineering 108(10), 2348-2358.
157. Padlan EA. (1990) X-ray diffraction studies of antibody constant regions. In: Fc Receptors and the Action of Antibodies. Metzger H, ed., 12-30. American Society for Microbiology, Washington, DC.
158. Pan H, Chen K, Chu L, et al. (2009) Methionine oxidation in human IgG2 Fc decreases binding affinities to protein A and FcRn. Protein Science 18(2), 424-433.
159. Pascoe DE, Arnott D, Papoutsakis ET, et al. (2007) Proteome analysis of antibody-producing CHO cell lines with different metabolic profiles. Biotechnology and Bioengineering 98(2), 391-410.
160. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, et al. (2008) Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112(6), 2390-2399.
161. Perez-Garmendia R, Gevorkian G. (2013) Pyroglutamate-modified amyloid beta peptides:emerging targets for Alzheimer’s disease immunotherapy. Current Neuropharmacology 11(5), 491-498.
162. Pointreau Y, Commins SP, Calais G, et al. (2012) Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis. Journal of Clinical Oncology 30(3), 334-335.
163. Qian J, Liu T, Yang L, et al. (2007) Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Analytical Biochemistry 364(1), 8-18.
164. Radaev S, Motyka S, Fridman WH, et al. (2001) The structure of a human type III Fc receptor in complex with Fc. Journal of Biological Chemistry 276(19), 16469-16477.
165. Raju TS, Jordan RE. (2012) Galactosylation variations in marketed therapeutic antibodies. MAbs 4(3), 385-391.
166. Raju TS, Lang SE. (2014) Diversity in structure and functions of antibody sialylation in the Fc. Current Opinions in Biotechnology 30, 147-152.
167. Ramsland PA, Farrugia W, Bradford TM, et al. (2011) Structural basis for FcRIIa recognition of human IgG and formation of inflammatory signaling complexes. Journal of Immunology 187(6), 3208-3217.
168. Reeves PJ, Callewaert N, Contreras R, Khorana HG. (2002) Structure and function in rhodopsin: high-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line. Proceedings of National Academy of Science USA 99(21), 13419-13424.
169. Reusch D, Haberger M, Falck D, et al. (2015a) Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 2: mass spectrometric methods. MAbs 7(4), 732-742.
170. Reusch D, Haberger M, Maier B, et al. (2015b) Comparison of methods for the analysis of therapeutic immunoglobulin G Fc-glycosylation profiles-Part 1: separation-based methods. MAbs 7(1), 167-179.
171. Ripka J, Adamany A, Stanley P. (1986) Two Chinese hamster ovary glycosylation mutants affected in the conversion of GDP-mannose to GDP-fucose. Archives of Biochemistry and Biophysics 249(2), 533-545.
172. Rispens T, Davies AM, Ooijevaar-de Heer P, et al. (2014) Dynamics of inter-heavy chain interactions in human immunoglobulin G (IgG) subclasses studied by kinetic Fab arm exchange. Journal of Biological Chemistry 289(9), 6098-6109.
173. Rispens T, Meesters J, den Bleker TH, et al. (2013) Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer. Molecular Immunology 53(1-2), 35-42.
174. Rojko JL, Evans MG, Price SA, et al. (2014) Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies. Toxicology and Pathology 42(4), 725-764.
175. Rombouts Y, Ewing E, van de Stadt LA, et al. (2015) Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Annals of Rheumatic Diseases 74(1), 234-241.
176. Royer PJ, Emara M, Yang C, et al. (2010) The mannose receptor mediates the uptake of diverse native allergens by dendritic cells and determines allergen-induced T cell polarization through modulation of IDO activity. Journal of Immunology 185(3), 1522-1531.
177. Ruhaak LR, Uh HW, Beekman M, et al. (2011) Plasma protein N-glycan profiles are associated with calendar age, familial longevity and health. Journal of Proteome Research 10(4), 1667-1674.
178. Sacco F, Perfetto L, Castagnoli L, Cesareni G. (2012) The human phosphatase interactome:an intricate family portrait. FEBS Letters 586(17), 2732-2739.
179. Sanz I, Anolik JH, Looney RJ. (2007) B cell depletion therapy in autoimmune diseases. Frontiers of Bioscience 12, 2546-2567.
180. Sauer-Eriksson AE, Kleywegt GJ, Uhlen M, Jones TA. (1995) Crystal structure of the C2 fragment of streptococcal protein G in complex with the Fc domain of human IgG. Structure 3(3), 265-278.
181. Schiel JE, Davis DL, Borisov OV. (2014a) State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1. Monoclonal Antibody Therapeutics: Structure, Function, and Regulatory Space. American Chemical Society, Washington, DC.
182. Schiel JE, Mire-Sluis A, Davis D. (2014b) Monoclonal antibody therapeutics: the need for biopharmaceutical reference materials. In: State-of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 1. Monoclonal Antibody Therapeutics: Structure, Function, and Regulatory Space. Schiel JE, Davis DL, Borisov OV, eds., 1-34. American Chemical Society, Washington, DC.
183. Schwab I, Biburger M, Kronke G, et al. (2012) IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. European Journal of Immunology 42(4), 826-830.
184. Schwab I, Nimmerjahn F. (2014) Role of sialylation in the anti-inflammatory activity of intravenous immunoglobulin-F(ab’)(2) versus Fc sialylation. Clinical and Experimental Immunology 178(Suppl. 1), 197-199.
185. Sealover NR, Davis AM, Brooks JK, et al. (2013) Engineering Chinese hamster ovary (CHO) cells for producing recombinant proteins with simple glycoforms by zinc-finger nuclease (ZFN)-mediated gene knockout of mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (Mgat1). Journal of Biotechnology 167(1), 24-32.
186. Shi HH, Goudar CT. (2014) Recent advances in the understanding of biological implications and modulation methodologies of monoclonal antibody N-linked high mannose glycans. Biotechnology and Bioengineering 111(10), 1907-1919.
187. Shibata-Koyama M, Iida S, Misaka H, et al. (2009a) Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcRIIIb and MHC class II expression on the phagocytotic neutrophils. Experimental Hematology 37(3), 309-321.
188. Shibata-Koyama M, Iida S, Okazaki A, et al. (2009b) The N-linked oligosaccharide at FcRIIIa Asn-45: an inhibitory element for high FcRIIIa binding affinity to IgG glycoforms lacking core fucosylation. Glycobiology 19(2), 126-134.
189. Shields RL, Lai J, Keck R, et al. (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcRIII and antibody-dependent cellular toxicity. Journal of Biological Chemistry 277(30), 26733-26740.
190. Sinclair AM. (2013) Erythropoiesis stimulating agents: approaches to modulate activity. Biologics 7, 161-174.
191. Singh PK, Devasahayam M, Devi S. (2015) Expression of GPI anchored human recombinant erythropoietin in CHO cells is devoid of glycosylation heterogeneity. Indian Journal of Experimental Biology 53(4), 195-201.
192. Sinha S, Zhang L, Duan S, et al. (2009) Effect of protein structure on deamidation rate in the Fc fragment of an IgG1 monoclonal antibody. Protein Science 18(8), 1573-1584.
193. Sjogren J, Struwe WB, Cosgrave EF, et al. (2013) EndoS2 is a unique and conserved enzyme of serotype M49 group A Streptococcus that hydrolyses N-linked glycans on IgG and α1-acid glycoprotein. Biochemical Journal 455(1), 107-118.
194. Skulj M, Pezdirec D, Gaser D, et al. (2014) Reduction in C-terminal amidated species of recombinant monoclonal antibodies by genetic modification of CHO cells. BMC Biotechnology 14, 76.
195. Sondermann P, Huber R, Oosthuizen V, Jacob U. (2000) The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcRIII complex. Nature 406(6793), 267-273.
196. Sondermann P, Pincetic A, Maamary J, et al. (2013) General mechanism for modulating immunoglobulin effector function. Proceedings of the National Academy of Science USA 110(24), 9868-9872.
197. Song T, Ozcan S, Becker A, Lebrilla CB. (2014) In-depth method for the characterization of glycosylation in manufactured recombinant monoclonal antibody drugs. Analytical Chemistry 86(12), 5661-5666.
198. Spencer S, Bethea D, Raju TS, et al. (2012) Solubility evaluation of murine hybridoma antibodies. MAbs 4(3), 319-325.
199. Stanfield RL, Wilson IA. (2014) Antibody structure. Microbiology Spectra 2(2), doi:10.1128/microbiolspec.AID-0012-2013.
200. Stanley P. (2011) Golgi glycosylation. Cold Spring Harbour Perspectives in Biology 3(4), a005199.
201. Stork R, Zettlitz KA, Muller D, et al. (2008) N-glycosylation as novel strategy to improve pharmacokinetic properties of bispecific single-chain diabodies. Journal of Biological Chemistry 283(12), 7804-7812.
202. Subedi GP, Hanson QM, Barb AW. (2014) Restricted motion of the conserved immunoglobulin G1 N-glycan is essential for efficient FcRIIIa binding. Structure 22(10), 1478-1488.
203. Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. (2012) Mogamulizumab: first global approval. Drugs 72(9), 1293-1298.
204. Tang L, Sundaram S, Zhang J, et al. (2013) Conformational characterization of the charge variants of a human IgG1 monoclonal antibody using H/D exchange mass spectrometry. MAbs 5(1), 114-125.
205. Tsubaki M, Terashima I, Kamata K, Koga A. (2013) C-terminal modification of monoclonal antibody drugs: amidated species as a general product-related substance. International Journal of Biological Macromolecules 52, 139-147.
206. Umana P, Jean-Mairet J, Moudry R, et al. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nature Biotechnology 17(2), 176-180.
207. Vafa O, Gilliland GL, Brezski RJ, et al. (2014) An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 65(1), 114-126.
208. van de Winkel JG. (2010) Fc receptors: role in biology and antibody therapy. Immunology Letters 128(1), 4-5.
209. Vidarsson G, Dekkers G, Rispens T. (2014) IgG subclasses and allotypes: from structure to effector functions. Frontiers of Immunology 5, 520.
210. Vlasak J, Bussat MC, Wang S, et al. (2009) Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Analytical Biochemistry 392(2), 145-154.
211. Voice JK, Lachmann PJ. (1997) Neutrophil Fc and complement receptors involved in binding soluble IgG immune complexes and in specific granule release induced by soluble IgG immune complexes. European Journal of Immunology 27(10), 2514-2523.
212. Wacker C, Berger CN, Girard P, Meier R. (2011) Glycosylation profiles of therapeutic antibody pharmaceuticals. European Journal of Pharmaceutics and Biopharmaceutics 79(3), 503-507.
213. Wang W, Singh S, Zeng DL, et al. (2007) Antibody structure, instability, and formulation. Journal of Pharmaceutical Sciences 96(1), 1-26.
214. Wang W, Vlasak J, Li Y, et al. (2011) Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Molecular Immunology 48(6-7), 860-866.
215. Washburn N, Schwab I, Ortiz D, et al. (2015) Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proceedings of National Academy of Science USA 112(11), E1297-1306.
216. Welle S. (1999) Human Protein Metabolism. Springer-Verlag New York Inc., New York.
217. Wiegandt A, Meyer B. (2014) Unambiguous characterization of N-glycans of monoclonal antibody cetuximab by integration of LC-MS/MS and (1)H NMR spectroscopy. Analytical Chemistry 86(10), 4807-4814.
218. Wu SJ, Luo J, O’Neil KT, et al. (2010) Structure-based engineering of a monoclonal antibody for improved solubility. Protein Engineering Design & Selection 23(8), 643-651.
219. Wuhrer M, Stavenhagen K, Koeleman CA, et al. (2015) Skewed Fc glycosylation profiles of anti-proteinase 3 immunoglobulin G1 autoantibodies from granulomatosis with polyangiitis patients show low levels of bisection, galactosylation, and sialylation. Journal of Proteome Research 14(4), 1657-1665.
220. Wypych J, Li M, Guo A, et al. (2008) Human IgG2 antibodies display disulfide-mediated structural isoforms. Journal of Biological Chemistry 283(23), 16194-16205.
221. Xie H, Chakraborty A, Ahn J, et al. (2010) Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. MAbs 2(4), 379-394.
222. Yamada E, Tsukamoto Y, Sasaki R, et al. (1997) Structural changes of immunoglobulin G oligosaccharides with age in healthy human serum. Glycoconjugation Journal 14(3), 401-405.
223. Yamaguchi Y, Nishimura M, Nagano M, et al. (2006) Glycoform-dependent conformational alteration of the Fc region of human immunoglobulin G1 as revealed by NMR spectroscopy. Biochimica Biophysica Acta 1760(4), 693-700.
224. Yamane-Ohnuki N, Satoh M. (2009) Production of therapeutic antibodies with controlled fucosylation. MAbs 1(3), 230-236.
225. Yan SCB, Razzano P, Chao YB, et al. (1990) Characterization and novel purification of recombinant human protein C from three mammalian cell lines. Bio-Technology 8(7), 655-661.
226. Yang H, Zubarev RA. (2010) Mass spectrometric analysis of asparagine deamidation and aspartate isomerization in polypeptides. Electrophoresis 31(11), 1764-1772.
227. Yang YS, Wang CC, Chen BH, et al. (2015) Tyrosine sulfation as a protein post-translational modification. Molecules 20(2), 2138-2164.
228. Yin S, Pastuskovas CV, Khawli LA, Stults JT. (2013) Characterization of therapeutic monoclonal antibodies reveals differences between in vitro and in vivo time-course studies. Pharmaceutical Research 30(1), 167-178.
229. Youings A, Chang SC, Dwek RA, Scragg IG. (1996) Site-specific glycosylation of human immunoglobulin G is altered in four rheumatoid arthritis patients. Biochemical Journal 314(Pt. 2), 621-630.
230. Yu C, Crispin M, Sonnen AF, et al. (2011a) Use of the α-mannosidase I inhibitor kifunensine allows the crystallization of apo CTLA-4 homodimer produced in long-term cultures of Chinese hamster ovary cells. Acta Crystallographica, Section F, Structural Biology and Crystallization Communications 67(Pt. 7), 785-789.
231. Yu M, Brown D, Reed C, et al. (2012) Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans. MAbs 4(4), 475-487.
232. Yu M, Hu Z, Pacis E, et al. (2011b) Understanding the intracellular effect of enhanced nutrient feeding toward high titer antibody production process. Biotechnology and Bioengineering 108(5), 1078-1088.
233. Yu X, Vasiljevic S, Mitchell DA, Crispin M, Scanlan CN. (2013) Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain. Journal of Molecular Biology 425(8), 1253-1258.
234. Zeck A, Pohlentz G, Schlothauer T, et al. (2011) Cell type-specific and site directed N-glycosylation pattern of FcRIIIa. Journal of Proteome Research 10(7), 3031-3039.
235. Zhang P, Chan KF, Haryadi R, et al. (2013) CHO glycosylation mutants as potential host cells to produce therapeutic proteins with enhanced efficacy. Advances in Biochemical Engineering and Biotechnology 131, 63-87.
236. Zhang W, Voice J, Lachmann PJ. (1995) A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes. Clinical and Experimental Immunology 101(3), 507-514.
237. Zheng K, Bantog C, Bayer R. (2011) The impact of glycosylation on monoclonal antibody conformation and stability. MAbs 3(6), 568-576.
238. Zhong X, Cooley C, Seth N, et al. (2012) Engineering novel Lec1 glycosylation mutants in CHO-DUKX cells: molecular insights and effector modulation of N-acetylglucosaminyltransferase I. Biotechnology and Bioengineering 109(7), 1723-1734.
239. Zhong X, Wright JF. (2013) Biological insights into therapeutic protein modifications throughout trafficking and their biopharmaceutical applications. International Journal of Cell Biology 2013, 273086.
240. Zhou Q, Shankara S, Roy A, et al. (2008) Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnology and Bioengineering 99(3), 652-665.